Insulet (NASDAQ:PODD) Hits New 12-Month High – Time to Buy?

Insulet Corporation (NASDAQ:PODD)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $354.88 and last traded at $339.5140, with a volume of 210854 shares changing hands. The stock had previously closed at $346.36.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Barclays lifted their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Rothschild & Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Jefferies Financial Group lifted their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. UBS Group upgraded Insulet from a “neutral” rating to a “buy” rating and lifted their price target for the company from $355.00 to $400.00 in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $376.35.

Insulet Price Performance

The stock has a market cap of $23.41 billion, a PE ratio of 100.70, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company’s fifty day moving average is $322.93 and its 200 day moving average is $314.19.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. Inspire Investing LLC boosted its stake in Insulet by 299.5% in the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after buying an additional 3,088 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in Insulet by 41.3% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock valued at $3,780,000 after purchasing an additional 3,514 shares during the last quarter. Gradient Investments LLC acquired a new position in Insulet in the second quarter valued at about $17,429,000. Goldman Sachs Group Inc. boosted its position in Insulet by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares in the last quarter. Finally, Marshall Financial Group LLC bought a new stake in Insulet during the second quarter worth about $943,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.